[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vacthera” connections=”true” suffix=””]

Oncolytic viruses are a novel type of tumor immunotherapy complementing standard therapies including checkpoint inhibitors. Viruses are engineered to conditionally replicate in cancer tissue leading to tumor destruction by stimulation of the immune system. The founders of Vacthera were the first to generate an oncolytic virus for the influenza virus family. Currently the development is in a preclinical stage.